Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $7.5

Benzinga · 5d ago
Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:TDOC) with a Neutral and lowers the price target from $11 to $7.5.